FEELM
14.5.2023 17:06:34 CEST | Business Wire | Press release
FEELM launched its new innovative disposable vape solution FEELM Max, at the Vaper Expo UK 2023 in Birmingham on May 13.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230514005039/en/
Johnny Zhang, The Assistant President at FEELM (Photo: Business Wire)
As a leading vaping technology provider and flagship brand of atomization tech company SMOORE, FEELM unveiled the advanced FEELM Max solution which boasts three major breakthroughs: the advanced heating technology of the Ceramic Coil S1, a constant power control system and mindful design.
With the first products featuring the FEELM Max solution about to launch in the UK and EU markets, the launch was attended by many top level representatives from many client companies including BAT, RELX International, Totally Wicked, and KIWI.
Setting New 800-Puff Benchmark for 2 ML E-Liquid
The coil technology journey began with first-generation cotton wick coils, progressed to second-generation cotton mesh coil, and has now developed into the era of third-generation ceramic coil technology with the FEELM Max being the latest manifestation of this industry innovation.
Designed to deliver a superior vaping experience, the innovative FEELM Ceramic Coil S1 brings cutting-edge coil technology that offers an increased puff count, setting a new benchmark in the market.
Benefitting from its cotton-free design and the resulting improvement of e-liquid utilization, the FEELM Max is able to boost puff count by more than 30% compared to cotton coil disposable solutions, providing 800 more puffs and setting a new benchmark for 2ml. This innovation allows products using the FEELM Ceramic Coil S1 to offer increased puff counts while remaining totally compliant with all local regulations.
In addition, the new S1 coil decreases the amount of impurities from the heating process by 78%, resulting in fresher breath and no unpleasant aftertaste. This is a significant stride towards ensuring a clean and silky vaping experience for consumers.
Electronic and Design Breakthroughs
The FEELM Max solution uses a constant power energy management system for stable vaping and over 95% vapor consistency. This technology improves taste consistency by 35%, which further enhances the user experience.
FEELM Max products showcase a transparent e-liquid tank for both aesthetics and user convenience. No longer will vapers have to guess how much e-liquid is left in their device because one quick look will let them know. The CMF Lab refines this design through specialized research and has developed a scientific ergonomic model for the vaping industry.
First Industrial End-To-End Whole-Chain Recycling Scheme
FEELM has also launched the first industrial whole-chain recycling scheme, collaborating with RELX International in the UK. Conscious of the potential harm of vapes ending up in landfills, FEELM has taken the responsibility for implementing a scheme that will facilitate vape recycling to a fuller extent, thereby minimising the environmental impact.
The company's commitment to making recycling more accessible demonstrates its dedication to environmental sustainability. As the initiative gains traction, it could serve as a model for other industries looking to implement eco-friendly practices and engage adult customers in sustainability efforts.
Shaping a Sustainable and Compliant Future with Partners
FEELM's success is not solely due to its innovative technology and the relentless pursuit of excellence, but also the strong collaboration it has forged with its clients and industry partners.
Bing Du, the CEO and founder of RELX International stated at the event: “Thanks to the groundbreaking technology of FEELM Max, and driven by our legendary partnership with FEELM, RELX International is on course to revolutionize the vaping experience across the globe.”
Liam Cagliarini, UK CEO of KIWI Vapor, the leading Italian brand, stated: "We aim to collaborate with FEELM on latest technology, and provide a consistency vaping experience for consumers."
Marcus Saxton, CEO of Totally Wicked, top British brand, added: "FEELM’s innovative technology has enhanced the consumer experience. As a partner of FEELM, Totally Wicked shares the responsibility of promoting sustainability in the atomization industry through active participation in the recycling system."
FEELM intends to continue pushing the boundaries of what's possible in vaping technology, while keeping its commitment to sustainability and compliance at the heart of its operations. The company's mission to shape a better vaping industry, not only for today but for generations to come, remains stronger than ever.
About FEELM
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE
Founded in 2009, SMOORE is a global leader in atomization technology solutions, covering reduced-risk products, medical, pharmaceutical, and beauty atomization technologies. With inter-disciplinary atomization research and a diverse product portfolio, SMOORE is committed to becoming an advanced platform, aspired to make life better.
With continuous R&D investment and leading manufacturing capacity, SMOORE has 14 technology research centers worldwide and products are available in more than 50 countries and regions. SMOORE announced IPO in Hong Kong on July 10, 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230514005039/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom